Cargando…
Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
EML4–ALK fusion, observed in about 3%–7% of human lung adenocarcinoma, is one of the most important oncogenic drivers in initiating lung tumorigenesis. However, it still remains largely unknown about how EML4–ALK fusion exactly fires downstream signaling and drives lung cancer formation. We here fin...
Autores principales: | Qin, Zhen, Sun, Honghua, Yue, Meiting, Pan, Xinwen, Chen, Liang, Feng, Xinhua, Yan, Xiumin, Zhu, Xueliang, Ji, Hongbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113584/ https://www.ncbi.nlm.nih.gov/pubmed/33976114 http://dx.doi.org/10.1038/s41421-021-00270-5 |
Ejemplares similares
-
Phase‐separated foci of EML4‐ALK facilitate signalling and depend upon an active kinase conformation
por: Sampson, Josephina, et al.
Publicado: (2021) -
Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018) -
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022) -
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022) -
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)